Predicine is a molecular information company developing genomic profiling tests and robust algorithms for cancer diagnostics and monitoring. It has developed a portfolio of regulated liquid biopsy genomic products to help advance the science of precision medicine in cancer. The company offers 600 gene-panel to facilitate biomarker-driven patient enrollment in clinical trials. Predicine's biology-oriented approach to analyzing genomics is advancing the understanding of tumor mutational landscape. With its vast data sets and advanced analytics, Predicine partners with 30+ biopharma to support their clinical trials in the US, EU, Australia, and China.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.